Outputs

Home  /  Outputs (Page 2)

EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment. PTJA13 addresses ‘satralizumab indicated for the treatment of patients ≥12 years with neuromyelitis optica spectrum disorders (NMOSD)’, submitted by Roche. We are delighted that INFARMED, EUR (Erasmus

  Patient group input requested for a new Joint Assessment on a medicinal product for acute myeloid leukaemia. EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique

EUnetHTA is pleased to announce the start of the next Pharmaceutical Joint Assessment. PTJA12 addresses ‘Glasdegib indicated for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML)’, submitted by Pfizer. We are delighted that HVB and

Patient group input requested for a new Joint Assessment on a medicinal product for the prevention of vaso-occlusive crises in sickle cell disease (SCD) patients aged 16 years and over. EUnetHTA deems patient involvement very important in the production of

EUnetHTA is pleased to announce that the final project plan, final assessment, comments from the external experts and authors' answers, together with the final abstract and plain language summary for OTCA19 "Screening for osteoporosis in the general population'' are now

We are pleased to announce that, as of today, the draft methodological guideline "Practical considerations when critically assessing economic evaluations", produced within WP6 B2, has entered the public consultation phase. This consultation will be open until 11th October, 2019.   Objective of the